Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer

Clin Pharmacol Ther. 1994 Aug;56(2):190-201. doi: 10.1038/clpt.1994.123.

Abstract

Pharmacokinetics of total platinum, 5-fluorouracil, l-folinic and d-folinic acid, and 5-methyltetrahydrofolate were studied in plasma from nine patients with advanced colorectal cancer treated with oxaliplatin (20 mg/m2/day), 5-fluorouracil (600 mg/m2/day), and folinic acid (300 mg/m2/day). Drugs were administered with a programmable-in-time pump by continuous infusion for 5 days. We compared two drug delivery schedules: constant rate versus chronomodulated rate with peak of oxaliplatin at 4 pm and peak of 5-fluorouracil and folinic acid at 4 am. In the chronomodulated schedule, plasma concentrations of the drugs paralleled the pump functioning: maximum platinum concentration near 4 pm, and maximum 5-fluorouracil and folate concentrations near 4 am. When drugs were administered at a constant rate, mean plasma concentration of 5-fluorouracil varied in a circadian manner each treatment day, that is, a peak at 4 am (approximately 800 ng/ml) and a trough at 1 pm (approximately 100 ng/ml). Mean plasma levels of total platinum and folate compounds increased over the first 24 hours. Total platinum mean level and that of the inactive d-folinic acid isomer reached a constant plasma concentration, whereas biologically active folates exhibited circadian variation in their plasma concentrations (peak around 7 am, trough near 6 pm, and amplitude approximately 10%). Severe mucositis was exhibited by all four patients on the flat schedule, but only by one on the chronomodulated schedule (p < 0.008). Individual pharmacokinetic and toxicity data showed that patients with circadian rhythms in 5-fluorouracil concentrations were least sensitive to 5-fluorouracil-related toxicity. Thus amplification or induction of such rhythm in 5-fluorouracil exposure may permit dose escalation.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Analysis of Variance
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / blood*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Circadian Rhythm*
  • Colorectal Neoplasms / blood*
  • Colorectal Neoplasms / drug therapy
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / blood*
  • Fluorouracil / pharmacokinetics
  • Fluorouracil / therapeutic use
  • Folic Acid / blood
  • Humans
  • Infusion Pumps
  • Leucovorin / administration & dosage
  • Leucovorin / blood*
  • Leucovorin / pharmacokinetics
  • Leucovorin / therapeutic use
  • Male
  • Middle Aged
  • Mouth Mucosa / drug effects
  • Organoplatinum Compounds / administration & dosage
  • Organoplatinum Compounds / blood*
  • Organoplatinum Compounds / pharmacokinetics
  • Organoplatinum Compounds / therapeutic use
  • Oxaliplatin
  • Stereoisomerism
  • Stomatitis / chemically induced
  • Tetrahydrofolates / blood

Substances

  • Organoplatinum Compounds
  • Tetrahydrofolates
  • Oxaliplatin
  • Folic Acid
  • Leucovorin
  • 5-methyltetrahydrofolate
  • Fluorouracil